Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts ASRT Hot Sheet
Join SI Premium – FREE
Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.7 million versus the consensus estimate of $28.87 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nutrien warns shareholders about below-market mini-tender offer
- TechCreate Group faces NYSE American delisting proceedings
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
